Artal Group’s MacroGenics MGNX Stock Holding History

Artal Group’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-100,000	Closed	-$1.9M	–	128
2017 Q4	$1.9M	Sell	100,000 -100,000	-50%	-$1.87M	0.03%	97
2017 Q3	$3.7M	Sell	200,000 -100,000	-33%	-$1.73M	0.06%	73
2017 Q2	$5.25M	Hold	300,000	–	–	0.09%	59
2017 Q1	$5.58M	Buy	300,000 +100,000	+50%	+$1.93M	0.12%	58
2016 Q4	$4.09M	Buy	200,000 +50,000	+33%	+$1.26M	0.09%	57
2016 Q3	$4.49M	Buy	+150,000	New	+$4.46M	0.09%	62

Other funds holding MGNX

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Artal Group's MGNX Position: Q1 2018 in Review

Artal Group sold out of MacroGenics (MGNX) in Q1 2018, closing a stake of 100,000 shares — an estimated $1.9M sold.

Artal Group first reported a position in MGNX in Q3 2016 and held it in 6 quarters. The position peaked at $5.58M in Q1 2017. 132 funds tracked by Wall St. Rank hold MGNX as of Q1 2018.

Artal Group reported no remaining MacroGenics position as of Q1 2018 after selling out during the quarter.
Artal Group sold 100,000 MacroGenics shares in Q1 2018, an estimated $1.9M.
Artal Group first reported a position in MacroGenics in Q3 2016 and held it in 6 quarters.
Artal Group's MacroGenics position peaked at $5.58M in Q1 2017.
132 funds tracked by Wall St. Rank held MacroGenics as of Q1 2018.

Based on Artal Group's 13F filing for Q1 2018, filed 10 May 2018.